Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jun;71(6):1302–1307. doi: 10.1038/bjc.1995.252

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

J A Gietema 1, G J Veldhuis 1, H J Guchelaar 1, P H Willemse 1, D R Uges 1, A Cats 1, H Boonstra 1, W T van der Graaf 1, D T Sleijfer 1, E G de Vries 1, et al.
PMCID: PMC2033845  PMID: 7779728

Abstract

In phase I studies, lobaplatin showed activity in ovarian cancer patients pretreated with platinum. A phase II trial with lobaplatin was performed in patients with refractory or relapsed ovarian cancer to define activity and pharmacokinetics. Twenty-two patients were treated with lobaplatin administered as an intravenous bolus every 4 weeks. Dependent on creatinine clearance (CRCL) patients received 30 or 50 mg m-2 lobaplatin as the starting dose. Twenty-two patients received 78 courses (median 3, range 1-6). In eight patients total platinum (TPt) in plasma and urine, free platinum (FPt) in plasma ultrafiltrate (both measured by atomic absorption spectrometry) and lobaplatin in plasma ultrafiltrate measured (by high-performance liquid chromatography) were measured. Toxicity was confined to mild nausea and vomiting, mild leucocytopenia (WHO grade 3 in 18% of the courses), and renal function-related thrombocytopenia (WHO grade 3/4 in 53% of the courses). A correlation was found between CRCL and reduction in platelet count (r = -0.77; P < 0.01). No renal toxicity was encountered. Five of 21 evaluable patients (24%) achieved a response (four complete remissions and one partial remission). Remissions occurred mainly in patients who relapsed more than 6 months after primary treatment. The median survival from start of lobaplatin treatment was 8 months. The mean areas under the curve (AUCs) were 4.2 +/- 0.5, 3.0 +/- 0.6, and 3.2 +/- 1.1 h mgl-1 for TPt, FPt and lobaplatin respectively. The free platinum fraction (FPt/TPt) was initially very high, indicating low protein binding. FPt was essentially present as intact lobaplatin. Four hours after infusion 54 +/- 5% and 24 h after infusion 74 +/- 3% of the lobaplatin dose was excreted in the urine. In conclusion, lobaplatin is a platinum compound with anti-tumour activity in patients with relapsed ovarian cancer, especially in those who have platinum-sensitive tumours. The main toxicity of lobaplatin is thrombocytopenia and its dose should be corrected according to renal function.

Full text

PDF
1302

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Green S., Hannigan E. V., O'Toole R., Stock-Novack D., Anderson P., Surwit E. A., Malvlya V. K., Nahhas W. A., Jolles C. J. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992 May;10(5):706–717. doi: 10.1200/JCO.1992.10.5.706. [DOI] [PubMed] [Google Scholar]
  2. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989 Apr;59(4):650–653. doi: 10.1038/bjc.1989.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  4. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  5. Dobbs S. P., Gribbin C., Chan S. Y., Bessell E. M. Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin. Eur J Cancer. 1994;30A(1):30–33. doi: 10.1016/s0959-8049(05)80013-9. [DOI] [PubMed] [Google Scholar]
  6. Egorin M. J., Van Echo D. A., Tipping S. J., Olman E. A., Whitacre M. Y., Thompson B. W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44(11):5432–5438. [PubMed] [Google Scholar]
  7. Evans B. D., Raju K. S., Calvert A. H., Harland S. J., Wiltshaw E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep. 1983 Nov;67(11):997–1000. [PubMed] [Google Scholar]
  8. Gaver R. C., Colombo N., Green M. D., George A. M., Deeb G., Morris A. D., Canetta R. M., Speyer J. L., Farmen R. H., Muggia F. M. The disposition of carboplatin in ovarian cancer patients. Cancer Chemother Pharmacol. 1988;22(3):263–270. doi: 10.1007/BF00273422. [DOI] [PubMed] [Google Scholar]
  9. Gietema J. A., Guchelaar H. J., de Vries E. G., Aulenbacher P., Sleijfer D. T., Mulder N. H. A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anticancer Drugs. 1993 Feb;4(1):51–55. doi: 10.1097/00001813-199302000-00007. [DOI] [PubMed] [Google Scholar]
  10. Gietema J. A., de Vries E. G., Sleijfer D. T., Willemse P. H., Guchelaar H. J., Uges D. R., Aulenbacher P., Voegeli R., Mulder N. H. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer. 1993 Feb;67(2):396–401. doi: 10.1038/bjc.1993.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Guchelaar H. J., Uges D. R., Aulenbacher P., de Vries E. G., Mulder N. H. Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions. Pharm Res. 1992 Jun;9(6):808–811. doi: 10.1023/a:1015815908347. [DOI] [PubMed] [Google Scholar]
  12. Harland S. J., Newell D. R., Siddik Z. H., Chadwick R., Calvert A. H., Harrap K. R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44(4):1693–1697. [PubMed] [Google Scholar]
  13. Kavanagh J. J., Nicaise C. Carboplatin in refractory epithelial ovarian cancer. Semin Oncol. 1989 Apr;16(2 Suppl 5):45–48. [PubMed] [Google Scholar]
  14. LeRoy A. F., Wehling M. L., Sponseller H. L., Friauf W. S., Solomon R. E., Dedrick R. L., Litterst C. L., Gram T. E., Guarino A. M., Becker D. A. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med. 1977 Oct;18(2):184–191. doi: 10.1016/0006-2944(77)90089-8. [DOI] [PubMed] [Google Scholar]
  15. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J. L., Jr Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991 Mar;9(3):389–393. doi: 10.1200/JCO.1991.9.3.389. [DOI] [PubMed] [Google Scholar]
  16. Meijer C., Mulder N. H., Timmer-Bosscha H., Sluiter W. J., Meersma G. J., de Vries E. G. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992 Dec 15;52(24):6885–6889. [PubMed] [Google Scholar]
  17. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Vriesendorp R., Kooyman C. D., van Lindert A. C., Hamerlynck J. V., van Lent M., van Houwelingen J. C. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet. 1984 Sep 15;2(8403):594–600. doi: 10.1016/s0140-6736(84)90594-4. [DOI] [PubMed] [Google Scholar]
  18. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
  19. Omura G., Blessing J. A., Ehrlich C. E., Miller A., Yordan E., Creasman W. T., Homesley H. D. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 1;57(9):1725–1730. doi: 10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  20. Swenerton K., Jeffrey J., Stuart G., Roy M., Krepart G., Carmichael J., Drouin P., Stanimir R., O'Connell G., MacLean G. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992 May;10(5):718–726. doi: 10.1200/JCO.1992.10.5.718. [DOI] [PubMed] [Google Scholar]
  21. Thigpen J. T., Vance R. B., Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 1993 Feb 15;71(4 Suppl):1559–1564. doi: 10.1002/cncr.2820710422. [DOI] [PubMed] [Google Scholar]
  22. Weiss G., Green S., Alberts D. S., Thigpen J. T., Hines H. E., Hanson K., Pierce H. I., Baker L. H., Goodwin J. W. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. Eur J Cancer. 1991;27(2):135–138. doi: 10.1016/0277-5379(91)90470-x. [DOI] [PubMed] [Google Scholar]
  23. Williams C. J., Mead G. M., Macbeth F. R., Thompson J., Whitehouse J. M., MacDonald H., Harvey V. J., Slevin M. L., Lister T. A., Shepherd J. H. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol. 1985 Nov;3(11):1455–1462. doi: 10.1200/JCO.1985.3.11.1455. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES